The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT)

NCT04881227 | Completed

• 1 other identifier: APHP210173.2
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Vaccine hesitancy also concerns healthcare workers (HCWs). However, HCWs are at the frontline of the COVID-19 pandemic and identified as a priority target group for COVID-19 vaccines. Thus, the identification of interventions likely to improve COVID-19 vaccine attitudes and intentions among HCWs is of interests to increase the vaccine coverage among HCWs. The study hypothesis is that the use of the same chatbot as the one tested in the general population in France could also improve the COVID-19 vaccine intentions and perceptions in HCWs.

Conditions

Healthcare Workers; Covid19

Outcome Measures

Primary Outcomes (1)

• The change in the COVID-19 vaccine perceptions (5 questions) using a seven-point Likert scale, immediately after the access to the intervention

  1. "I think vaccines against COVID-19 are safe" 2. "I think vaccines against COVID-19 are effective" 3. "I think we know enough about the COVID-19 vaccines" 4. "I think we can trust the people who produce the COVID-19 vaccines" 5. "I think it is important to get vaccinated against COVID-19". The COVID-19 vaccine perceptions variable is the mean of the response to these five questions, each answered on a 7-point likert scale.

  Change from baseline to immediately after intervention (experimental or control arm)

Secondary Outcomes (5)

• The change in the COVID-19 vaccine perceptions (5 questions) using a seven-point Likert scale, 15-days after the access to the intervention

  From baseline to day 15

• The change in the COVID-19 vaccine intention, immediately after the access to the intervention with the following question: "Do you personally intent to be vaccinated against COVID-19?"

  From baseline to immediately after the intervention (experimental or control arm)

• The change in the COVID-19 vaccine intention, 15 days after the access to the intervention with the following question: "Do you personally intent to be vaccinated against COVID-19?" (yes, as soon as possible / yes but I prefer to wait / no)

  From baseline to day 15 after the intervention (experimental or control arm)

• Changes into the attitudes and intention towards the COVID-19 vaccines according to the vaccine immediately and 15-days after the access to the interventions

  Up to 15 days

• Participants in the Chatbot intervention will be ask, after the access to the intervention, to answer to a satisfaction questionnaire

  End of baseline questionnaire

Study Arms (2)

Chatbot condition

EXPERIMENTAL

Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.

Device: Chatbot on COVID-19 vaccine hesitancy

Control condition

ACTIVE COMPARATOR

Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.

Other: Control intervention

Interventions

Chatbot on COVID-19 vaccine hesitancy DEVICE

This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.

Chatbot condition

Control intervention OTHER

This control intervention will provide to participants a brief text decribing the way vaccines works.

Control condition

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Legal age
• Healthcare workers defined as individuals who currently work in a setting where individuals receive healthcare (i.e. individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as administrative office, housekeeping, food service, etc.)
• Included in ESPERES cohort and with the initial questionnaire completed
• Agreeing to participate (digital consent)

You may not qualify if:

• No internet access
• Vaccinated against COVID-19 (at least one dose)

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Pitié-Salpêtrière - Charles Foix, AP-HP

Paris, Île-de-France Region, 75013, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Florence Tubach, MD, PhD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 10, 2021
• First Posted: May 11, 2021
• Study Start: May 25, 2021
• Primary Completion: September 23, 2021
• Study Completion: October 15, 2021
• Last Updated: June 21, 2022

Record last verified: 2022-06

Locations

FR (1)